XML 62 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 36 Months Ended
Jun. 30, 2016
May 31, 2016
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
May 31, 2020
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Business Acquisition [Line Items]                  
Accrued liabilities       $ 1,676,467 $ 1,678,051        
Goodwill       $ 1,452,338 $ 2,189,338        
Percentage of non-controlling interest acquired       15.00% 15.00%        
Revenue       $ 3,049,104 $ 5,793,849        
Net loss (income)       (20,017,568) (15,733,854)        
Net loss       $ 20,384,716 $ 16,591,293        
Pelican Therapeutics, Inc.                  
Business Acquisition [Line Items]                  
Ownership interest in subsidiary       85.00% 85.00%   85.00% 80.00%  
Pelican Therapeutics, Inc.                  
Business Acquisition [Line Items]                  
Percentage of voting interests acquired in acquisition       85.00% 80.00%       80.00%
Fair value of contingent consideration         $ 200,000        
Percentage of non-controlling interest acquired       20.00%          
Amount awarded from CPRIT grant $ 15,200,000 $ 15,200,000       $ 15,200,000      
Pelican Therapeutics, Inc. | Stockholders                  
Business Acquisition [Line Items]                  
Cash consideration     $ 300,000